Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Vismodegib,VISMO001,2021,USA,MDV,350,72,35.0,65.0,27.5,42.0,85.0,0.0,15.0,30.0,40.0,15.0,60.0,25.0,10.0,5.0,20.0,35.0,45.0,18.0,8.0,5.0,12.0,7.0,5.0,10.0,25.0,Cisplatin + 5-FU,Carboplatin + Paclitaxel,5-FU,Capecitabine,0.0,0.0,0.0,30.0,40.0,50.0,20.0,50.0,30.0,40.0,2
Vismodegib,VISMO002,2022,Germany,Claim Database,420,75,40.0,60.0,28.0,38.0,80.0,0.0,12.0,28.0,45.0,15.0,55.0,30.0,10.0,5.0,18.0,32.0,50.0,20.0,10.0,6.0,14.0,8.0,7.0,12.0,28.0,Carboplatin + Docetaxel,Cisplatin + Gemcitabine,Gemcitabine,Docetaxel,0.0,0.0,0.0,35.0,45.0,55.0,15.0,55.0,30.0,45.0,3
Vismodegib,VISMO003,2023,UK,MDV,280,70,30.0,70.0,26.8,45.0,90.0,0.0,18.0,32.0,35.0,15.0,65.0,20.0,10.0,5.0,22.0,38.0,40.0,15.0,7.0,4.0,10.0,6.0,3.0,8.0,22.0,5-FU + Leucovorin,Carboplatin + Pemetrexed,Capecitabine,Vinorelbine,0.0,0.0,0.0,25.0,35.0,45.0,25.0,45.0,30.0,35.0,1
Vismodegib,VISMO004,2024,Canada,Claim Database,480,73,38.0,62.0,29.0,40.0,82.0,0.0,14.0,29.0,42.0,15.0,58.0,27.0,10.0,5.0,19.0,34.0,47.0,19.0,9.0,5.5,13.0,7.5,6.0,11.0,26.0,Cisplatin + Docetaxel,Carboplatin + Gemcitabine,Gemcitabine,Paclitaxel,0.0,0.0,0.0,32.0,42.0,52.0,18.0,52.0,30.0,42.0,2.5
